You said,
"One point that happens to be correct is that if the OS curves really do separate as many longs hope, the trial would already be highly stat sig. It is fair to question why the trial is still ongoing."
My comments:
Nobody has ever looked at unblinded data since the disband of DMC in the summer 2015, except reports of safety issues if any by clinicians and/or CRO, caregivers, etc.
In other words, nobody knows if there are any separations of OS between intended groups because the goal after Summer 2015 is to catch the thick and long tail if any, or Linda called it additional homerun.
That means even if Linda believes there are indeed separations in OS between the treatment arm and the standard care arm, or the earlier and later vaccinated arms, she has since determined to run the trial farther enough to catch that suspected long and thick tail.
She has in many occasions indicating they would not stop the trial at the initial intended events of either PFS or OS due to new developments, particularly the now well understood nature of immunotherapy in general.
Of course, one additional reason perhaps is that anyone in her position would also exercise caution, because the company has only this one shot.
Ex you seem to be evolving recently, what gives?
[Like Mav I am allowed for only one post a day so no offense for anyone who replies to my posts and gets no reply]
News 
Market Data 
Discover 
